| |
|
|
|
|
|
|
|||
|
FA Siddiqui and EC Lian
Hemophilia and Thrombosis Center, University of Miami School of Medicine,
FL.
We have previously reported the purification of a 37-kd platelet-
agglutinating protein (PAP p37) from the plasma of a patient with
thrombotic thrombocytopenic purpura (TTP) that was shown to be present in a
subset of TTP patients. The platelet agglutination induced by PAP p37 has
been shown to be inhibited by IgG from normal human adults and the same TTP
patient after recovery. To elucidate the mechanism of inhibition of IgG,
the interaction between PAP p37 and IgG was studied. The complex formation
was demonstrated by the binding of fluid-phase IgG from normal adults and
the same TTP patient after recovery to adsorbed PAP by using an
enzyme-linked immunosorbent assay. The binding was specific, concentration
dependent, and saturable. IgG purified from a 5-month-old baby and the same
TTP patient during active disease did not form complex with PAP p37. The
IgG covalently cross-linked to Sepharose 4B bound 125I-PAP p37 but not
125I-fibrinogen. Sucrose density gradient ultracentrifugation of a mixture
of 125I-PAP p37 and IgG also revealed the fluid-phase complex formation
with a sedimentation value of 19S. Complexes of molecular weight ranging
from 180,000 to over 350,000 daltons were also detected by molecular sieve
chromatography. The IgG that was bound to PAP p37 conjugated to Sepharose
4B inhibited the agglutination of washed platelets induced by TTP plasma
containing PAP p37, whereas the IgG that was not bound to PAP p37 did not
have a significant inhibitory effect. The complex formation between PAP p37
and specific IgG is likely to account for the in vitro inhibition of TTP
plasma-induced agglutination and, at least partly, the in vivo successful
treatment with specific IgG-containing normal plasma.
This article has been cited by other articles:
| |||||||||||
| Copyright © 1988 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||